ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Age-related macular degeneration severity and risk of Alzheimer's disease in older adults in a prospective, community-based cohort study.
Chloe A Krakauer, Luke Reilly, Yu-Ru Su, Rod L Walker, Dana Lee, Vilaipone A Xaiyamuangchanh, David J Cronkite, Nicole M Gatto, Paul K Crane, Emily Y Chew and 2 more
Abstract read
In one paragraphArticle in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Chloe A KrakauerKaiser Permanente Washington Health Research Institute Seattle Washington USA.
Luke ReillyWashington University School of Medicine St. Louis Missouri USA.
Yu-Ru SuKaiser Permanente Washington Health Research Institute Seattle Washington USA.
Rod L WalkerKaiser Permanente Washington Health Research Institute Seattle Washington USA.
Dana LeeKaiser Permanente Washington Health Research Institute Seattle Washington USA.
Vilaipone A XaiyamuangchanhDepartment of Ophthalmology University of Washington Seattle Washington USA.
David J CronkiteKaiser Permanente Washington Health Research Institute Seattle Washington USA.
Nicole M GattoKaiser Permanente Washington Health Research Institute Seattle Washington USA.
Paul K CraneDepartment of Medicine University of Washington Seattle Washington USA.
Emily Y ChewDivision of Epidemiology and Clinical Application National Eye Institute National Institutes of Health Bethesda Maryland USA.
David E ArterburnKaiser Permanente Washington Health Research Institute Seattle Washington USA.
Cecilia S LeeJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences Washington University in St. Louis St. Louis Missouri USA.
Funding
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Paul K Crane, Andrea Z. LaCroix · 2021 to 2026
$80.4MAging eyes and aging brains in studying alzheimer's disease: Modern ophthalmic data collection in the adult changes in thought (ACT) studyR01AG060942 · NIA · WASHINGTON UNIVERSITY · PI Cecilia Sungmin Lee · 2019 to 2026
$39.4MFurthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3MBridge2AI:Salutogenesis Data Generation ProjectOT2OD032644 · OD · WASHINGTON UNIVERSITY · PI BAXTER, SALLY LIU, CHUTE, CHRISTOPHER G · 2022 to 2025
$32.7MNIA NIH HHS R01 AG060942NIA NIH HHS U01 AG006781NIA NIH HHS U19 AG066567NIH HHS OT2 OD032644
6 · The paper itselfAbstract
introductionAge-related macular degeneration (AMD) is associated with higher risk of Alzheimer's disease (AD), but how AD risk changes as AMD progresses remains unclear.
methodsAmong participants in the Adult Changes in Thought study, we characterized the worst dry and wet AMD severities experienced to date on a scale of 0 to 10 and assessed whether they were associated with AD risk.
resultsAmong 2611 participants (550 AD cases, median 6.8 years follow-up), AD hazard was estimated to increase by 4% per one unit increase in dry and wet scores (dry: 95% confidence interval [CI] for hazard ratio [HR] 1.01 to 1.07, DISCUSSION: Worse AMD severity was associated with higher AD risk, with severity scores potentially offering greater clinical utility for AD risk characterization among individuals without diagnosed AMD.
Indexed as
age‐related macular degenerationAlzheimer's diseasebiomarkerclinical epidemiologydementiadry age‐related macular degenerationelectronic health recordsophthalmologyrisk surveillancewet age‐related macular degeneration
Identifiers
PMID42255955
PMCPMC13239676
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390